Who are AD-227A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): paliperidone clozapine, Any FDA approved antipsychotic agent, Risperidone and Ramelteon, Intramuscular olanzapine, aripiprazole, Aripiprazole tablet, full-dose olanzapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ad-227a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

AD-227A — Competitive Intelligence Brief

AD-227A (AD-227A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin receptor agonist. Area: Psychiatry.

phase 3 Serotonin receptor agonist 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

AD-227A (AD-227A) — Addpharma Inc.. AD-227A is a small molecule drug that targets the serotonin receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AD-227A TARGET	AD-227A	Addpharma Inc.	phase 3	Serotonin receptor agonist	5-HT2A receptor
paliperidone clozapine	paliperidone clozapine	Universidad Nacional de Rosario	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Any FDA approved antipsychotic agent	Any FDA approved antipsychotic agent	Vanguard Research Group	marketed	Antipsychotic (dopamine antagonist)	Dopamine D2 receptor (primary); serotonin 5-HT2A receptor and others (varies by agent)
Risperidone and Ramelteon	Risperidone and Ramelteon	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic + melatonin receptor agonist combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
Intramuscular olanzapine, aripiprazole	Intramuscular olanzapine, aripiprazole	Veterans Medical Research Foundation	marketed	Atypical antipsychotic	Dopamine D2 receptor; serotonin 5-HT2A receptor (olanzapine); dopamine D2 partial agonist (aripiprazole)
Aripiprazole tablet	Aripiprazole tablet	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic	Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (partial agonist); Serotonin 5-HT2A receptor (antagonist)
full-dose olanzapine	full-dose olanzapine	Kaohsiung Kai-Suan Psychiatric Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin receptor agonist class)

Addpharma Inc. · 1 drug in this class
Organon and Co · 1 drug in this class
Serenity Pharmaceuticals, Inc. · 1 drug in this class
University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AD-227A — Competitive Intelligence Brief. https://druglandscape.com/ci/ad-227a. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab